179062-00-1

Basic information

• Product Name: N-(4-bromo-2-nitro-6-trifluoromethyl-phenyl)-acetamide
• Synonyms: N-(4-bromo-2-nitro-6-trifluoromethyl-phenyl)-acetamide
• CAS NO: 179062-00-1
• Molecular Weight: 327.057
• Mol File: 179062-00-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: N-(4-bromo-2-nitro-6-trifluoromethyl-phenyl)-acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-bromo-2-nitro-6-trifluoromethyl-phenyl)-acetamide(179062-00-1)
• EPA Substance Registry System: N-(4-bromo-2-nitro-6-trifluoromethyl-phenyl)-acetamide(179062-00-1)

Safety Data

• Hazardous Substances Data: 179062-00-1(Hazardous Substances Data)

Upstream product

• 445-02-3 4-bromo-2-trifluoromethyl-aniline 
• 29124-62-7 N-(4-bromo-2-trifluoromethyl-phenyl)-acetamide 

Downstream Products

• 1326310-55-7 5-cyclopropyl-3-(trifluoromethyl)-1,2-benzenediamine 
• 1326310-54-6 4-cyclopropyl-2-nitro-6-(trifluoromethyl)aniline 
• 157026-19-2 5-bromo-3-(trifluoromethyl)-1,2-benzenediamine 
• 157026-18-1 4-bromo-2-nitro-6-trilfuoromethyl-phenylamine 

Relevant articles and documents

BENZIMIDAZOLE ANTIVIRAL AGENTS

Provided are compounds of Formula (I) and (II) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the Flaviviridae family of viruses such as hepatitis C virus (HCV).

Synthesis and structure-activity relationships of substituted 1,4- dihydroquinoxaline-2,3-diones: Antagonists of N-methyl-D-aspartate (NMDA) receptor glycine sites and non-NMDA glutamate receptors

A series of mono-, di-, tri-, and tetrasubstituted 1,4- dihydroquinoxaline-2,3-diones (QXs) were synthesized and evaluated as antagonists at N-methyl-D-aspartate (NMDA)/glycine sites and α-amino-3- hydroxy-5-methylisoxazole-4-propionic acid-preferring non-NMDA receptors. Antagonist potencies were measured by electrical assays in Xenopus oocytes expressing rat whole brain poly(A)+ RNA. Trisubstituted QXs 17a (ACEA 1021), 17b (ACEA 1031), 24a, and 27, containing a nitro group in the 5 position and halogen in the 6 and 7 positions, displayed high potency (K(b) ~ 6-8 nM) at the glycine site, moderate potency at non-NMDA receptors (K(b) = 0.9-1.5 μM), and the highest (120-250-fold) selectivity in favor of glycine site antagonism over non-NMDA receptors. Tetrasubstituted QXs 17d,e were more than 100-fold weaker glycine site antagonists than the corresponding trisubstituted QXs with F being better tolerated than Cl as a substituent at the 8 position. Di- and monosubstituted QXs showed progressively weaker antagonism compared to trisubstituted analogues. For example, removal of the 5-nitro group of 17a results in a ~100-fold decrease in potency (10a,b,z), while removal of both halogens from 17a results in a ~3000-fold decrease in potency (10v). In terms of steady-state inhibition, most QX substitution patterns favor antagonism at NMDA/glycine sites over antagonism at non-NMDA receptors. Among the QXs tested, only 17i was slightly selective for non- NMDA receptors.